Could a cancer drug quiet overactive adrenal hormones? a new study investigates.
NCT ID NCT07680205
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This pilot study looks at how belzutifan, a drug already used for some tumors, changes the production of adrenaline-like hormones in people with pheochromocytoma and paraganglioma (PPGL). Over 5 days, researchers measure key substances in the hormone-making process to see if belzutifan can lower excess hormone levels. The study involves 12 adults with confirmed PPGL and aims to understand the drug's effect on hormone metabolism.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belzutifan
What this could lead to
If successful, this could reveal how belzutifan alters hormone production in these rare tumors, potentially guiding future treatments.
What could go wrong
This is a very small, early pilot study with only 12 participants and a short 5-day treatment period, so results may not apply broadly or lead directly to new therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- 211At-MABG for advanced neuroendocrine cancers | NCT07661420
- NET-COMPARE: New PET Tracer for Neuroendocrine T NCT07621146
- 68Ga-DOTATOC PET/CT for NET Imaging - NCT03583528
- 68Ga-HA-DOTATATE PET/CT for Neuroendocrine Tumor NCT04888481
- Adrenal Tumor Study – Understanding & New Treatm NCT00669266
- PPGL Surgery Risk Prediction Study | NCT07516275
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cambridge University Hospitals NHS Foundation Trust
RECRUITINGCambridge, Cambridgeshire, CB2 0QQ, United Kingdom